References

Parkinson disease

10.1038/nrdp.2017.13 · 2017 · External reference

Biomarker‐driven phenotyping in Parkinson's disease: a translational missing link in disease‐modifying clinical trials

10.1002/mds.26913 · 2017 · External reference

Movement Disorder Society‐sponsored revision of the unified Parkinson's disease rating scale (MDS‐UPDRS): scale presentation and clinimetric testing results

10.1002/mds.22340 · 2008 · External reference

The Parkinson progression marker initiative (PPMI)

10.1016/j.pneurobio.2011.09.005 · 2011 · External reference

Item response theory analysis of the MDS‐UPDRS motor examination: tremor vs. nontremor items

10.1002/mds.28110 · 2020 · External reference

Developing and validating Parkinson's disease subtypes and their motor and cognitive progression

10.1136/jnnp-2018-318337 · 2018 · External reference

Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort

10.1002/mds.27361 · 2018 · External reference

Estimation of latent ability using a response pattern of graded scores

10.1007/bf03372160 · 1969 · External reference

Novel approach to Movement Disorder Society‐unified Parkinson's disease rating scale monitoring in clinical trials: longitudinal item response theory models

10.1002/mdc3.13311 · 2021 · External reference

Longitudinal evaluation of an abbreviated patient‐reported Movement Disorder Society‐sponsored revision of the unified Parkinson's disease rating scale (MDS‐UPDRS) for predicting dopaminergic therapy initiation in early Parkinson's disease

10.1002/mds.70096 · 2025 · External reference

Increasing sensitivity in patient‐reported MDS‐UPDRS items for predicting medication initiation in early PD

10.1002/mdc3.14229 · 2025 · External reference

Effect of urate‐elevating inosine on early Parkinson disease progression: the SURE‐PD3 randomized clinical trial

10.1001/jama.2021.10207 · 2021 · External reference

Predictors of cognitive impairment in an early stage Parkinson's disease cohort

10.1002/mds.25748 · 2014 · External reference

Isradipine versus placebo in early Parkinson disease: a randomized trial

10.7326/m19-2534 · 2020 · External reference

Trial of Prasinezumab in early‐stage Parkinson's disease

10.1056/nejmoa2202867 · 2022 · External reference

Trial of cinpanemab in early Parkinson's disease

10.1056/nejmoa2203395 · 2022 · External reference

How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale

10.1002/mds.25383 · 2013 · External reference

The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson's disease

10.1002/mds.23462 · 2011 · External reference

Optimizing the MDS‐UPDRS part III for early‐stage Parkinson's: early supportive evidence for a limb‐related bradykinesia/rigidity sub‐score

10.1038/s41531-025-01072-2 · 2025 · External reference